{
    "clinical_study": {
        "@rank": "8067", 
        "brief_summary": {
            "textblock": "An open label, prospective, non-randomized single arm study. Combination of two treatment\n      modalities - HAI with FUDR and systemic chemotherapy with cisplatin and gemcitabine.\n\n      Definition of the maximum tolerated dose (MTD) of intravenous gemcitabine in combination\n      with intravenous cisplatin and intra-arterial FUDR. Definition of safety and toxicity of\n      this combined regional and systemic treatment approach. Definition of the response rate\n      after 3 months of hepatic intra-arterial chemotherapy with continuous infusion FUDR with or\n      without ligation of the right or left portal vein, in combination with 3 months of systemic\n      cisplatin and gemcitabine in patients with unresectable intrahepatic or hilar CCC.\n\n      A total of 9-18 patients are required. 3-6 patients per dose level. A maximum of three dose\n      levels (1 - 3) has been defined.\n\n      Statistical Methodology: Traditional 3+3 dosing algorithm to find MTD.\n\n        -  Trial with medicinal product"
        }, 
        "brief_title": "Downsizing of Unresectable Cholangiocarcinoma by Combined Intravenous and Intra-arterial Chemotherapy", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Cholangiocellular Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Cholangiocarcinoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Histologically or cytologically proven cholangiocellular carcinoma including\n             gallbladder cancer.\n\n          -  Non-resectable cholangiocellular carcinoma as judged within an interdisciplinary\n             tumor-board including senior hepatobiliary surgeons. Non- resectability is based on\n             insufficient remnant liver volume.\n\n          -  Patient is not a candidate for liver transplantation\n\n          -  WHO Performance Score 0 or 1\n\n          -  No extrahepatic tumor, as evaluated by PET/CT scan of the chest and the\n             abdomen/pelvis with the exception of potentially resectable small lung nodules or\n             hilar lymph node involvement.\n\n          -  The assessment is done within 21 days before registration.\n\n          -  Adequate liver function or kidney function tests, including any of the following:\n\n               -  Bilirubin < 2 x ULN\n\n               -  Aspartate-Aminotransferase (AST) < 5 x ULN\n\n               -  Alanine-Aminotransferase (ALT) < 5 x ULN\n\n               -  Alkaline phosphatase < 5 x ULN\n\n               -  Estimated creatinine clearance > 60 ml/min (using the Cockcroft formula)\n\n          -  Adequate hematological values:\n\n               -  Hemoglobin > 80 G/L\n\n               -  Leucocytes > 3.00 G/L,\n\n               -  Neutrophils > 1.00 G/Ll\n\n               -  Platelets > 100 G/L\n\n          -  Signed written informed consent\n\n          -  Patient age >/= 18 years\n\n          -  Presentation of the case at the interdisciplinary tumor-board attended by\n             hepatobiliary surgeons, oncologists, hepatologists and radiologists\n\n          -  Women who are not breastfeeding and are using effective contraception if sexually\n             active, who are not pregnant and agree not to become pregnant during the 12 months\n             thereafter. A negative pregnancy test before inclusion into the trial is required for\n             women < 50 years.\n\n          -  Men who agree not to father a child during participation in the trial or during the\n             12 months thereafter.\n\n          -  Patient compliance and geographic proximity allow proper staging and follow- up.\n\n        Exclusion criteria:\n\n          -  Anatomic variant in arteriogram which prevents selective delivery of the chemotherapy\n             to the liver\n\n          -  Life expectancy < 3 months\n\n          -  Severe medical or psychiatric co-morbidity prohibiting the planned treatment or the\n             giving of informed consent\n\n          -  Any man or woman of childbearing age in case of inadequate contraception\n\n          -  Pregnancy or breastfeeding woman\n\n          -  Known hypersensitivity to trial drugs or hypersensitivity to any other component of\n             the trial drugs.\n\n          -  Treatment in clinical trial within 30 days prior to trial entry.\n\n          -  Active heart disease defined as congestive heart failure > NYHA class 2\n\n          -  Past or current history (within the last 2 years prior to treatment start) of other\n             malignancies except basal and squamous cell carcinoma of the skin or in situ\n             carcinoma of the cervix\n\n          -  Inability or unwillingness to comply with the study protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01692704", 
            "org_study_id": "ONK-USZ-003"
        }, 
        "intervention": {
            "description": "Intra-arterial floxuridine:0.2 mg/KG/day for 14 days, repeated day 29. Overall 3 applications.\nSystemic cisplatin: 25 mg/m2 at days 1 and 8, repeated day 22. Overall 8 applications.\nSystemic gemcitabine: Three different dose levels will be tested; 600 mg/m2, 800 mg/m2, or 1000 mg/m2, at days 1 and 8, repeated day 22. Overall 8 applications.", 
            "intervention_name": "Selective intra-arterial floxuridine and systemic gemcitabine and cisplatin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Cisplatin", 
                "Floxuridine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Zurich", 
                    "country": "Switzerland", 
                    "state": "ZH", 
                    "zip": "8091"
                }, 
                "name": "University Hospital Zurich, Department of Oncology"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "1", 
        "official_title": "Downstaging of Unresectable Intrahepatic or Hilar Cholangiocellular Carcinoma by Selective Intra-arterial Floxuridine and Systemic Cisplatin and Gemcitabine. A Dose Finding Single Center Phase IIa Study", 
        "overall_contact": {
            "email": "panagiotis.samaras@usz.ch", 
            "last_name": "Panagiotis Samaras, MD"
        }, 
        "overall_official": {
            "affiliation": "University Hospital Zurich, Department of Oncology", 
            "last_name": "Panagiotis Samaras, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Dose limiting toxicities will be assessed to define the maximum tolerated dose (MTD) of gemcitabine in combination with fixed doses of cisplatin and FUDR. DLTs are per protocol prespecified AE or laboratory abnormalities observed during the first 6 weeks of study treatment. The MTD is one dose level below the dose level that caused DLTs in \u2265 one third of patients (2 or more in a cohort of 6 patients), as determined by a traditional 3+3 algorithm.", 
            "measure": "Dose limiting toxicities (DLT) of intravenous gemcitabine with concomitant administration of FUDR-HAI and intravenous cisplatin.", 
            "safety_issue": "Yes", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01692704"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Zurich", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Zurich", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}